Evaluation of Complete Pathological Regression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients with BRCA1 Founder Mutation Aided Bayesian A/B Testing Approach

The aim of this study was to evaluate the probability of pathologic complete regression (pCR) by the BRCA1 gene mutation status in patients with triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy. The study involved 143 women (mean age 55.4 ± 13.1 years) with TNBC. The BRCA1...

Descripción completa

Detalles Bibliográficos
Autores principales: Kedzierawski, Piotr, Macek, Pawel, Ciepiela, Izabela, Kowalik, Artur, Gozdz, Stanislaw
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306462/
https://www.ncbi.nlm.nih.gov/pubmed/34201809
http://dx.doi.org/10.3390/diagnostics11071144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306462/
https://www.ncbi.nlm.nih.gov/pubmed/34201809
http://dx.doi.org/10.3390/diagnostics11071144

Ejemplares similares